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Oncogenic RAS proteins are commonly expressed in human
cancer. To be functional, RAS proteins must undergo post-
translationalmodification and localize to the plasmamembrane
(PM). Therefore, compounds that prevent RAS PM targeting
have potential as putative RAS inhibitors. Here we examine the
mechanism of action of oxanthroquinone G01 (G01), a recently
described inhibitor ofKRASPM localization.We show thatG01
mislocalizesHRAS andKRAS from the PMwith similar potency
and disrupts the spatial organization of RAS proteins remaining
on the PM. G01 also inhibited recycling of epidermal growth
factor receptor and transferrin receptor, but did not impair
internalization of cholera toxin, indicating suppression of recy-
cling endosome function. In searching for the mechanism of
impaired endosomal recycling we observed that G01 also
enhanced cellular sphingomyelin (SM) and ceramide levels and
disrupted the localization of several lipid and cholesterol
reporters, suggesting that the G01molecular target may involve
SM metabolism. Indeed, G01 exhibited potent synergy with
other compounds that target SMmetabolism in KRAS localiza-
tion assays. Furthermore, G01 significantly abrogated RAS-
RAF-MAPK signaling in Madin-Darby canine kidney (MDCK)
cells expressing constitutively activated, oncogenic mutant
RASG12V. G01 also inhibited the proliferation of RAS-less
mouse embryo fibroblasts expressing oncogenic mutant
KRASG12V or KRASG12D but not RAS-less mouse embryo
fibroblasts expressing oncogenic mutant BRAFV600E. Consist-
ent with these effects, G01 selectively inhibited the proliferation
of KRAS-transformed pancreatic, colon, and endometrial cancer
cells. Taken together, these results suggest that G01 should
undergo further evaluation as a potential anti-RAS therapeutic.
RAS is a small guanine nucleotide-binding protein that oper-
ates as a molecular switch to regulate cell growth, proliferation,
and differentiation. RAS oscillates between an inactive GDP-
bound state and an active GTP-bound state, regulated by gua-
nine nucleotide exchange factors and GTPase-activating pro-
teins. Oncogenic mutations that lock RAS in the GTP-bound
state occur in15% of all human cancers, leading to constitu-
tive activation of downstream effectors (1, 2). Activated point
mutations occur in all ubiquitously expressed RAS isoforms,
HRAS,NRAS, andKRAS, but aremost prevalent inKRAS (3, 4).
To function, RAS proteins must localize to the inner leaflet of
the plasmamembrane (PM)2 (5). This is achieved through a set
of three post-translational modifications of the C-terminal
CAAX motif, common to all RAS proteins, which generate a
C-terminal cysteine farnesyl carboxyl-methyl ester (6). HRAS,
NRAS, andKRAS4A are additionally palmitoylated on adjacent
cysteine residues to generate a complete PM anchor (6, 7). In
the case of KRAS4B (referred to as KRAS hereafter), the farne-
sylated C-terminal cysteine operates in concert with a C-termi-
nal polybasic domain for PM localization (8).
Maintenance of RAS proteins on the PM requires one of two
distinct spatial organizing systems. HRAS and NRAS undergo
depalmitoylation by a thioesterase after endocytosis, resulting
in release to the cytosol. Following repalmitoylation in the
Golgi, HRAS, and NRAS are trafficked back to the PM via
vectorial exocytic transport (9–12), possibly via the recycling
endosome (RE) (13). A recent study shows that vacuolar protein
sorting-associated protein 35 (VPS35), a component of the ret-
romer complex, facilitates NRAS recycling from endosomes to
the Golgi complex (14). KRAS released to the cytosol following
endocytosis is captured by the chaperone protein PDE, which
delivers it to the RE for forward transport back to the PM. PDE
maintainsKRASas a soluble complex in the cytosol until the com-
plex isdisassembledbyArl2 in thevicinityof theRE.KRASrebinds
to negatively chargedRE vesicles for forward transport back to the
PM (15). These trafficking and recycling pathways are essential to
maintain the fidelity of RAS PM localization. For instance, inhibi-
tors of the RAS thioesterase that block the removal of palmitoyl
groups fromHRASandNRAScause entropic redistributionof the
proteins to all cellmembranes (10). Similarly, blockingPDE func-
tion with chemical inhibitors results in redistribution of KRAS
from the PM to endomembrane (15).
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Blocking RAS PM localization abrogates RAS biological
function, because effector activation occurs exclusively on the
PM (5). Inhibitors of CAAX processing, including farnesylation
with farnesyltransferase inhibitors, have not been successful
becauseKRAS andNRAS can be alternately geranylgeranylated
in farnesyltransferase inhibitor-treated cells and localize nor-
mally to the PM (16, 17). Inhibitors of the various components
of the RAS spatial organizing systemsmay, however, havemerit
(5, 18, 19). In the case of KRAS, PMphosphatidylserine (PtdSer)
content has also been shown to be critically important forKRAS
localizationand functionbecause theKRASanchor exhibits ahigh
degree of binding specificity for PtdSer (4, 20, 21). Thus drugs that
deplete the PM of PtdSer mislocalize and inhibit KRAS function;
these includemultiple inhibitors and regulators of sphingomyelin
(SM)biosynthesis andmetabolism (22–24).Wealso reportedpre-
viously a novel class of Streptomyces polyketide, the oxanthroqui-
nones, which mislocalize KRAS from the PM (25). In the context
of the recent studies described above clarifying the molecular
machineries that maintain KRAS PM binding, we explored the
putativemechanismof action of a representative derivative, oxan-
throquinone G01 (G01).
Results
G01mislocalizes oncogenic KRAS, KRAS4A, and HRAS from the
plasmamembrane
We reported previously the synthesis of a series of oxanthro-
quinone derivatives based on the original microbial polyketide
structures identified in a high content screen for inhibitors of
KRAS PM binding (25). The most potent synthetic compound
was 3-O-methyl oxanthroquinone ethyl ester, with a structure
as shown in Fig. 1A (25), and hereafter referred to as G01. We
selected G01 for further analysis. We first examined the
RAS isoform specificity of G01. Madin-Darby canine kidney
(MDCK) cells stably co-expressingmGFP-KRASG12V,mGFP-
HRASG12V, or mGFP-KRAS4AG12V, and mCherry-CAAX, a
general endomembrane marker, were treated with different
concentrations of G01 for 48 h, and analyzed by confocal
microscopy (26). The extent of RASG12V mislocalization was
calculated usingManders coefficients, which quantify the frac-
tion of mGFP-RASG12V co-localizing with mCherry-CAAX
(27). The greater the value of theManders coefficient, themore
extensive is the displacement of mGFP-RASG12V from the
PM. The results show that G01 mislocalizes oncogenic KRAS,
HRAS, and KRAS4A from the PM with approximately equal
potencies, the dose-response curves yielding IC50 values of1
M (Fig. 1, B and C).
G01 impairs spatial organization of RAS on the PM
In addition to PM subcellular localization, the lateral spatial
organization of RAS proteins into nanoclusters on the PM is
critical for RAS signal transmission (4). To quantify the effect
of G01 on RASG12V nanoclustering, intact basal PM sheets
from MDCK cells expressing mGFP-KRASG12V, mGFP-
HRASG12V, or mGFP-KRAS4AG12V were treated with G01
for 48 h, labeledwith gold-conjugated anti-GFP antibodies, and
analyzed by electronmicroscopy (EM). Spatialmapping of each
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Figure 1.Mislocalization of KRASG12V, HRASG12V, KRAS4AG12V from the PM is induced byG01. A, structure of G01. B,MDCK cells stably coexpressing
mCherry-CAAX, an endomembrane marker, and mGFP-KRASG12V, mGFP-HRASG12V, or mGFP-KRAS4A G12V were seeded on coverslips and treated with
vehicle (DMSO) or G01 for 48 h. Cells were imaged in a confocal microscope. Representative images of vehicle (DMSO), 1 and 5M G01 treatments are shown.
C, the extent of RAS mislocalization was quantified with Manders coefficients, which evaluate the extent of colocalization of mCherry-CAAX and mGFP-
RASG12V. Estimated IC50 values for G01 on each cell line were obtained from the respective Manders coefficient (mean S.E., n 3) dose-response plots.
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RAS protein on the PM revealed significant decreases in the
peak values of the L(r)–r clustering statistic, Lmax (Fig. 2A),
indicating a reduction in the amount of nanoclustered
KRASG12V, HRASG12V, and KRAS4AG12V on the PM. We
also observed a significant reduction in anti-GFP immunogold
labeling of each RAS isoform after G01 treatment, again show-
ing that G01 significantly depleted KRAS, HRAS, and KRAS4A
from the inner leaflet of the PM (Fig. 2B), concordant with the
confocal imaging results (Fig. 1, B and C).
G01 enhances cellular levels of sphingomyelin and ceramide
Recent studies have implicated SMmetabolism in the main-
tenance of normal PM lipidomic content and organization that
are critical for both KRAS and HRAS membrane binding and
nanoclustering (22, 23). To determine whether G01 disrupts
SMmetabolism, we first measured SM and ceramide (Cer) lev-
els using whole cell lipidomics. MDCK cells treated with G01
for 48 h exhibited significantly increased SM and Cer levels
(Fig. 3A). The enhancement in SM levelwas confirmedby stain-
ing with mGFP-lysenin that specifically binds SM.MDCK cells
were treated with G01 for 48 h and incubated with mGFP-
lysenin with and without membrane permeabilization. Images
were obtained with a confocal microscope. Concordant with
the lipidomic analysis, G01 enhancedmGFP-lysenin staining of
the exofacial leaflet of the PM as well as intracellular mem-
branes (Fig. 3, B and C). Disrupted SM metabolism may result
in mislocalization of PtdSer and cholesterol from the PM (24).
MDCK cells stably co-expressing mCherry-CAAX and mGFP-
LactC2, a probe for PtdSer, were treated with G01 for 48 h and
analyzed by quantitative confocal microscopy. The results
show that G01 disrupts the PM localization of mGFP-LactC2,
and by inference PtdSer, albeit with a potencymuch lower than
that against RAS (Fig. 3D). Similarly, when MDCK cells stably
co-expressingmCherry-D4H, a cholesterol probe, were treated
with G01 for 48 h, the mCherry-D4H probe was mislocalized
from the PMand accumulated in intracellular puncta, but again
this effect was only observedwith higher concentrations of G01
(Fig. 3E).
G01 synergizes with other compounds that disrupt SM
metabolism
To explore the potential molecular mechanism of action of
G01, we tested for synergism between G01 and three other
compounds that disrupt SM metabolism: fumonisin B1 (FB1),
staurosporine (STS), and R-fendiline. The premise being com-
pounds that have differentmolecular targets in a commonmet-
abolic pathway that is involved in maintaining KRAS PM local-
izationmay exhibit synergism for KRAS redistribution. FB1 is a
Cer synthase inhibitor that decreases cellular SM andCer levels
(24). STS when used at very low concentrations, well below the
IC50 for protein kinase C inhibition (22), increases the rate of
SM synthesis by decreasing the level of ORMDL proteins,
which negatively regulate the enzyme serine-palmitoyltrans-
ferase (24). R-fendiline is an inhibitor of acid sphingomyelinase.
R-fendiline treatment therefore elevates the SM content of the
endolysomal system (22, 23). We treated MDCK cells coex-
pressing mGFP-KRASG12V and mCherry-CAAX with various
concentrations of G01, in the presence of a fixed low concen-
tration (10 M) of FB1 for 48 h and imaged the cells using con-
focal microscopy, Manders coefficients were measured and
IC50 valueswere calculated.G01 alonemislocalizesKRASG12V
with an IC50 of1 M, whereas FB1 improves the IC50 to0.2
M (Fig. 4A). To formally quantify synergism, we calculated a
combination index (CI) using the Chou-Talalay method. By
this method a CI of 1 indicates an additive effect, a CI  1
indicates synergism, and a CI  1 indicates antagonism (28).
This analysis confirms that G01 synergizes with FB1 for KRAS
mislocalization over most of the G01 concentration ranges
tested (Table 1A). Reciprocally, a low dose of G01 shifted the
dose-response curve of FB1 to the left indicating a reduced IC50
(Fig. 4A). Chou-Talalay analysis again confirmed synergism
over most of the FB1 concentration range tested (Table 1A).
Similar experiments with G01 and STS, G01 and R-fendiline
showed strong synergism between each pair of compounds for
KRAS mislocalization from the PM (Fig. 4, B and C; Table 1, B
andC). These results strongly suggest that themolecular target
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Figure 2. G01 disrupts the PM nanoscale organization of KRASG12V,
HRASG12V, and KRAS4A G12V. A, basal PM sheets were generated from
MDCK cells stably expressing mGFP-KRASG12V, mGFP-HRASG12V, or mGFP-
KRAS4A G12V treated with vehicle (DMSO) or 1 M G01 for 24 h and imaged
by EM after labeling with anti-GFP antibody conjugated to 4.5-nm gold. The
extent of clustering of the gold particles was analyzed using Ripley’s K-func-
tion expressed as L(r) r functions and normalized on the 99% CI. The max-
imumvalue of L(r) r,defined as Lmax is used as a summary statistic. Values of
Lmax above the CI indicates nanoclustering, with the extent of clustering
being reflected by the Lmax value. At least 12 PM sheets were evaluated for
each condition and RAS isoform. Significant differences from the control pat-
tern for G01-treated cellswere assessed usingbootstrap tests (***, p 0.001).
B, average mean ( S.E., n 12) gold labeling density on the PM sheets was
calculated and the statistical significance of differences in gold labeling den-
sity was evaluated using Student’s t test (**, p 0.01; ***, p 0.001).
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of G01 impacts SM metabolism but is likely different from the
enzymes inhibited by FB1, STS, and R-fendiline.
G01 disrupts the endocytic recycling of epidermal growth
factor receptor and transferrin receptor
Normal function of the RE is required to maintain KRAS,
HRAS, and NRAS on the PM (13, 15). We therefore examined
whether G01 compromises the cellular distribution of other
proteins that recycle through the RE. We first observed the
localization and trafficking of epidermal growth factor receptor
(EGFR) (29–31). Chinese hamster ovary (CHO) cells stably
expressing mGFP-EGFR were treated with G01 for 48 h (or left
untreated), serumstarved, and incubatedwith EGFon ice for 15
min and then imaged by confocal microscopy at intervals fol-
lowing warming to 37 °C. For control cells with no G01 treat-
ment,mGFP-EGFRwas predominantly localized to the PMat 0
min and then rapidly endocytosed, such that at 15 and 30 min,
the majority of mGFP-EGFR was localized to intracellular ves-
icles, before being substantially returned to the PM by 60 min
(Fig. 5A). In G01-treated cells, a large fraction of mGFP-EGFR
was already redistributed from the PM at 0 min, and at subse-
quent time points the remaining PM-bound mGFP-EGFR was
internalized. In striking contrast to control cells at 60 min,
mGFP-EGFR was concentrated in the perinuclear region (Fig.
5A). In parallel experiments, we quantified the amount of
mGFP-EGFR on the PM during EGF-induced endocytosis
using anti-GFP immunogold labeling and EM of PM sheets.
The results are concordant with the confocal imaging and show
significantly lower levels of mGFP-EGFR on the PM in G01-
treated cells at 0 and 60 min (Fig. 5B). Together these data
illustrate that G01 inhibits the endocytic recycling of EGFR,
most probably, given the perinuclear accumulation of internal-
ized EGFR, by inhibiting the exit of EGFR from the RE.
We next examined endocytic recycling of the transferrin
receptor (TfR). Alexa Fluor 555-conjugated transferrin (Tf-
555) was bound to the surface of MDCK cells that had been
treated for 48 h with G01 or left untreated. Excess Tf-555 was
removed by washing and the cells immediately imaged. The
surface fluorescence intensity was much lower in the G01-
treated cells, indicating less bound Tf-555 and thus a lower
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Figure 3. SMmetabolism is disrupted inG01-treated cells.A,MDCK cells stably expressingmGFP-KRASG12V, orWTMDCK cellswere grown in the presence
of vehicle (DMSO) or 5 nM STS or 1MG01 for 48 h. Whole cell lysates were prepared and total SM and Cer levels weremeasured. The graph shows SM and Cer
levels relative to control, the significance of differenceswere assessed in one-way ANOVA using the actualmean lipid pmol values (mean S.E., n 3) (**, p
0.01; ***, p 0.001). B, WT MDCK cells were treated with G01 for 48 h, stained with mGFP-lysenin, and imaged in a confocal microscope with fixed imaging
parameters to assess comparative fluorescent intensities. The PMmGFP fluorescence intensity was quantified using the region of interest tool in ImageJ. The
values of fluorescence intensity were normalized to the mean of those in vehicle (DMSO) treated groups (mean S.E., n 20). The statistical significance of
differences in relative fluorescence intensity was assessed by one-way ANOVA (***, p  0.001). C, WT MDCK cells were treated with G01 for 48 h
and permeabilized, stained with GFP-lysenin and 4,6-diamidino-2-phenylindole (DAPI). Cells were imaged in a confocal microscope with fixed imaging
parameters. Representative imageswere shown.D,MDCKcells stably coexpressingmGFP-LactC2andmCherry-CAAXwere treatedwithG01 for 48h. Cellswere
fixed and imaged in a confocal microscope. Colocalization between mGFP-LactC2 and mCherry-CAAXwas quantified by Manders coefficients. The IC50 value
was estimated from the Manders coefficient (mean  S.E., n  3) dose-response plot. E, MDCK cells stably coexpressing mGFP-LactC2 and the cholesterol
probe, mCherry-D4H, were treated with G01 for 48 h. Cells were fixed and imaged in a confocal microscope. Representative images are shown.
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density of TfR on the PM (Fig. 6A). MDCK cells stably express-
ing mGFP-LactC2 were treated with G01 for 48 h, incubated
with Tf-555 on ice, then imaged by confocal microscopy at
intervals followingwarming to 37 °C. PtdSer is notmislocalized
by 1MG01 thereforeGFP-LactC2 can be used as a PMmarker
for quantification. In control cells Tf-555 was rapidly internal-
ized and substantially returned to the PM by 60 min; as shown
in the images in Fig. 6B that were quantified using Manders
coefficients to evaluate the extent of co-localization between
mGFP-LactC2 and Tf-555. Whereas in G01-treated cells
Tf-555was rapidly internalized but not returned to the PM (Fig.
6, B and C). These results together suggest that the endocytic
recycling of TfR is inhibited byG01.We next conducted similar
experiments with Alexa Fluor 647-conjugated cholera toxin b
subunit (CTB-647), using A431 cells that express the ganglio-
side GM1, which is the surface receptor for cholera toxin (32).
After initial incubation with CTB-647 we observed no differ-
ence in PM fluorescence intensity between G01-treated and
untreated cells, suggesting that the level of GM1 expressed on
the surface of A431 cells was unchanged byG01 treatment (Fig.
6A). To quantify the internalization of CTB-647 we stained
fixed cells with the impermeable PM marker Alexa Fluor 488
conjugated to wheat germ agglutinin (WGA-488) that binds
GlcNAc and N-acetylneuraminic acid. Manders coefficients
were then used tomeasure the rate of loss of CTB-647 from the
PM. This analysis revealed no difference in the kinetics of CTB-
647 internalization in A431 cells after G01 treatment (Fig. 7, A
and B). We therefore conclude that the internalization of GM1,
Table 1
G01 synergizes with modulators of SM metabolism for KRAS
mislocalization
Synergism was quantified by the Chou and Talalay method using Compusyn soft-
ware (version 1.0; ComboSyn, Inc.). Combination indexes (CI) were calculated
using the mean value of Manders coefficients from three independent experiments
(synergism, CI 1; additive effect, CI 1; antagonism, CI 1).
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Figure 4. The cocktails of G01with other compounds aremore potent for PMmislocalization of KRAS. A,MDCK cells stably coexpressingmCherry-CAAX and
mGFP-KRASG12Vwere treatedwith10MFB1with variable concentrationsofG01, or 0.5MG01with variable concentrationsof FB1. Cellswere fixedand imaged in
a confocal microscope. The colocalization betweenmGFP-LactC2 andmCherry-CAAXwas quantified byManders coefficients (mean S.E., n 3). IC50 values were
estimated from theManders coefficient dose-response plots. B,MDCK cells stably coexpressingmCherry-CAAX andmGFP-KRASG12V were treated with 0.5 nM STS
withvariable concentrationsofG01,or0.5MG01withvariable concentrationsof STS.Manders coefficients (meanS.E.,n3)werequantifiedand IC50 valueswere
estimated.C,MDCKcells stablycoexpressingmCherry-CAAXandmGFP-KRASG12Vwere treatedwith2.5MR-fendilinewithvariableconcentrationsofG01,or0.5M
G01with variable concentrations of R-fendiline. Manders coefficients (mean S.E., n 3) were quantified and IC50 valueswere estimated.
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which is not dependent on RE function, was unaffected by G01
treatment.
ERK signaling downstream of oncogenic RAS is abrogated
by G01
RASPM localization and nanocluster formation is critical for
signal transmission (5). Thus G01 concentrations that signifi-
cantly mislocalized KRASG12V or HRASG12V or KRAS4A
G12V also suppressed ppERK levels in MDCK cells stably
expressing each oncogenic RAS isoform (Fig. 8, A–C). Thus
oncogenic RAS-MAPK signaling is abrogated by G01. Given
that G01 synergizes with compounds that perturb SMmetabo-
lism for KRASG12V mislocalization, we also tested RAS-RAF-
MAPK signaling inMDCK cells expressing KRASG12V treated
with synergistic drug combinations. Concordant with the mis-
localization data shown in Fig. 4, treatment with 10 M FB1 or
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0.5 M G01 alone had no effect on pp-ERK levels, whereas the
drug combination significantly inhibited RAS-RAF-MAPK
signaling (Fig. 8D). Similar results were obtained with low
doses of G01 combined with low doses of STS, or R-fendi-
line, which singly had no effect on RAS-RAF-MAPK signal-
ing, but which in combination synergized to reduce ppERK
levels (Fig. 8, E and F).
G01 inhibits the proliferation of RAS-lessmouse embryonic
fibroblasts and KRAS transformed tumor cell lines
We first tested the effect of G01 on the proliferation of RAS-
less mouse embryonic fibroblast cells (MEF) expressing
KRASG12V, KRASG12D, or BRAFV600E. These are cell lines
generated fromKRAS-floxed, NRAS-null, andHRAS-nullmice
and express a single transgene that activates the mitogen-acti-
vated protein kinase (MAPK) pathway (33). Interestingly, 5 M
G01 treatment for 72 h significantly inhibited proliferation
of KRASG12V and KRASG12D RAS-less MEFs, but not
BRAFV600E RAS-lessMEFs (Fig. 9A). This result suggests that
G01 inhibits cell growth at the level of KRAS but not RAF,
consistent with an effect on KRAS PM binding. Finally, we
tested the efficacy of G01 on a selection on a panel of 14 pan-
creatic, lung, endometrial, and colon tumor cell lines, which
express WT or oncogenic mutant KRAS. G01 more potently
inhibited the proliferation of pancreatic, endometrial, and
colon tumor cells that expressed oncogenic KRAS (Fig. 9B).
G01 also inhibited the proliferation lung tumor cell lines, but
without evidence of increased potency in lines expressing onco-
genic mutant KRAS rather than WT KRAS (Fig. 9B).
Discussion
We show here, using fluorescence and EM that G01 potently
mislocalizes oncogenic KRAS, HRAS, and KRAS4A from the
PM to endomembranes. G01 also disrupts KRAS, HRAS, and
KRAS4A nanocluster formation. Concordant with previous
work showing that RAS PM localization and nanocluster for-
mation is crucial for biological function, G01-induced changes
to RAS cellular localization and PM spatial organization signif-
icantly abrogated RAF-MAPK signaling downstream of onco-
genic KRAS, HRAS, and KRAS4A. G01 also inhibited the pro-
liferation of RAS-less MEF cells expressing oncogenic KRAS
but not that of RAS-less MEFs expressing oncogenic BRAF,
confirming that inhibition was effected at the level of RAS. In
cancer cell proliferation assays, G01 more potently inhibited
the proliferation of pancreatic, colon, and endometrial tumor
cell lines that are oncogenic KRAS dependent, but had less
activity against the tumor cell lines that expressedWTKRAS or
were KRAS independent. This selectivity for KRAS function
was not observed in the small set of lung cancer cell lines we
examined, perhaps indicating that WT RAS signaling, which
would also be suppressed by G01, is required to support the
transformed phenotype in these lung cancer cell lines. Taken
A B
0 μM G01-
WGA-488
0 μM G01-
CTB-647
Merge
1 μM G01-
WGA-488
1 μM G01-
CTB-647
Merge
CTB-0 min CTB-15 min CTB-30 min CTB-60 min
0 h
15
 m
in
30
 m
in
60
 m
in
0.0
0.2
0.4
0.6
0.8
1.0
Time
M
an
de
rs
 C
oe
ffi
ci
en
t (
W
G
A)
0 μM G01
1 μM G01
Figure 7. Endocytosis of cholera toxin is unaffected byG01. A,A431 cells were treatedwith vehicle (DMSO) or 1MG01 for 48 h. Cells were incubatedwith
CTB-647 on ice for 20min. Excess CTB-647waswashed away by ice-cold PBS. Cells were then incubatedwith freshwarmmediumwith vehicle (DMSO) or 1M
G01 at 37 °C and fixed at different time points. Cells were incubated with WGA-488 for 10 min and fixed. Cells were imaged in a confocal microscope and
representative images of vehicle (DMSO), 1 M G01 are shown. B, images were analyzed using Manders coefficients to quantify colocalization of the PM
markers, WGA-488 and CTB-647. The statistical significance of differences between mean Manders coefficients (mean S.E., n 3) at each time point was
evaluated using Student’s t tests.
Inhibitor of RAS plasmamembrane interactions
13702 J. Biol. Chem. (2018) 293(??) 13696–13706
 at UQ Library on January 2, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
together, we conclude that G01 is a novel inhibitor of RAS PM
localization and function.
Several lines of evidence suggest that the mechanism of
action of G01 involves disruption of RE function. First, we
observedmislocalization of palmitoylated HRAS and KRAS4A,
as well as nonpalmitoylated KRAS4B with approximately equal
potency. This result implicates a common component of their
respective spatial organizing systems that maintains PM local-
ization after posttranslational processing, namely the RE (15).
Second, the EGFR and TfR were aberrantly distributed in G01-
treated cells concordantwith abnormal endocytic recycling (13,
15, 29–31), this was most evident with the EGFR, which accu-
mulated in the RE after G01 treatment in EGF-stimulated CHO
cells. It is probable that the effect of G01 on the RE function is a
consequence of elevated cellular SM levels. Similar effects have
been observed with other compounds. For example, blocking
ORMDL3 function with STS enhances de novo SM synthesis
(24, 27), and inhibiting acid sphingomyelinase with fendiline
increases SM and depletes ceramide levels (22, 23, 34). Pertur-
bation of SM levels by these two compounds results in lipid
loading of the endolysosomal compartment with SM and cho-
lesterol that impairs lipid recycling necessary to maintain the
PM lipidome. In consequence, PM PtdSer and cholesterol lev-
els are reduced (23). G01 also perturbs the PtdSer and choles-
terol content of the PM but at higher concentrations than that
at which changes to RAS localization are observed; thus the
induced changes to RE function by low dose G01 must affect
protein recycling more than lipid recycling at low doses, as
evident with the EGFR. Whereas the increase in SM levels
observed inG01-treated cellsmay be causative for abnormal RE
function, we cannot exclude the possibility that disrupted RE,
or endolysomal function by some other mechanism, could be
the primary target of G01 and that this in turn leads to second-
ary changes in SM levels.
We recently identified multiple enzymes in the SM meta-
bolic pathway whose pharmacological inhibition, or in some
cases pharmacological activation,mislocalize KRAS andPtdSer
from the PM (23). In this context we now show in KRAS mis-
localization assays that G01 synergizes with three inhibitors of
different SM metabolic enzymes. We propose therefore that
G01modulates SMmetabolism, but through amolecular target
different from those of FB1, R-fendiline, and STS. Interestingly
this synergy was observed with inhibitors that both up-regulate
anddown-regulate SM levels, indicating the critical importance
of PM SM lipid homeostasis in maintaining KRAS function.
Most interestingly, the synergistic effects onKRASmislocaliza-
tion also extended to synergistic inhibition of oncogenic KRAS-
driven MAPK activation. Together these results strongly sug-
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Figure 8. G01 inhibits oncogenic RAS signaling.MDCK cells stably expressing mGFP-KRASG12V (A), mGFP-HRASG12V (B), or mGFP-KRAS4A G12V (C) were
treated with vehicle (DMSO) or G01 for 48 h. Levels of ppERK were measured by quantitative immunoblotting and normalized to the total level of ERK.
Representative Western blots are shown. The significance of differences between mean ( S.E., n 3) drug-treated and control ppERK levels were assessed
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gest that G01 may have utility in drug cocktails for future anti-
RAS therapies.
Experimental procedures
Materials
Oxanthroquinone G01 was synthesized as described previ-
ously (25) and dissolved in dimethyl sulfoxide (DMSO). Cell
culture media and fetal bovine serum (FBS) were purchased
from HyClone, unless described otherwise. Rabbit anti-phos-
pho-p44/42MAPK (ppERK1/2) (Thr-202/Tyr-204) (9101) and
rabbit anti-ERK (4695) antibodies were purchased from Cell
Signaling Technology (Beverly, MA). Mouse anti--actin
(A1978) antibody was purchased from Sigma. Rabbit anti-
mGFP antibody for immunogold labeling was generated in
house. Transferrin fromhuman serum,Alexa FluorTM555 con-
jugate (T35352), cholera toxin subunit B (recombinant), Alexa
FluorTM 647 conjugate (C34778), and wheat germ agglutinin,
Alexa FluorTM 488 conjugate (W11261) were purchased from
Thermo Fisher Scientific.
Cell lines
BxPC3, MiaPaCa-2, and MOH were provided by Craig Logs-
don, KLE and Hec-1a cells by Karen Lu, Hec-1b cells by Bryan
Hennessey, and Hec-50 cells by Russell Broaddus, all at MD
Anderson Cancer Center, Houston, TX. Other cell lines were
purchased from the American Type Culture Collection
(ATCC) or provided by the NCI Ras Initiative. The MDCK,
A431 cell line, and RAS-less MEF were maintained in Dulbec-
co’s modified Eagle’s medium (GIBCO) supplemented with 2
mM L-glutamine and 10% FBS. CHO cells were maintained in
Ham’s F-12K medium (ATCC) supplemented with 10% FBS 2
mM L-glutamine. BxPC3,MOH, NCI-1975, NCI-23, NCI-2122,
NCI-441, and NCI-H508 cells were grown in RPMI 1640 sup-
plemented with 10% FBS. MiaPaCa-2 cells were grown in Dul-
becco’s modified Eagle’s medium supplemented with 10% FBS
and 2.5% horse serum. KLE and Hec-50 cells were maintained
in Dulbecco’s modified Eagle’s medium/F-12 medium supple-
mented with 10% FBS. Hec-1a and Hec-1b cells were grown in
McCoy’s 5a medium supplemented with 10% FBS. SK-CO-1
cells weremaintained in Eagle’sminimal essentialmedium sup-
plemented with 10% FBS. SW948 cells were grown in Leibo-
vitz’s L15 medium with 10% FBS.
Fluorescencemicroscopy
Cells were grown on coverslips and fixed with 4% parafor-
maldehyde (PFA). The coverslips weremounted inMowiol and
imaged in a confocal microscope (Nikon A1R) using a 	60 or
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Figure 9. G01 inhibits the proliferation of oncogenic KRAS-dependent cell lines. A, RAS-less MEF cells rescued by expressing KRASG12V, KRASG12D, or
BRAFV600E were seeded in 24-well plates and treated with vehicle (DMSO) or 5 M G01 for 48 h. The cells were detached and counted. For graphing cell
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	100 objective. The Manders coefficient plugin from ImageJ
was used for quantification.
EM and spatial analysis
MDCK cells expressing mGFP-tagged protein were seeded
on fibronectin-coated gold EM grids (IGG200, Ted Pella Inc.).
Cells were grown on the grids for 48 h. Apical PMwas removed
by placing aWhatman filter paper soaked in PBS onto the cells
for 5 min, applying brief pressure, and then removing the PBS-
soaked filter paper. The cytosolic surface of the adherent basal
PMwas exposed because the apical PMwas removed. The cyto-
solic leaflet of the basal PM was washed, fixed with PFA and
glutaraldehyde, and labeledwith anti-GFP antibody conjugated
to 4.5-nm gold particles. Digital images of intact immunogold-
labeled PM sheets were obtained via a JEOL 1400 transmission
electron microscope at 	100,000 magnification. Intact 1-m2
areas of the PM sheet were identified and the (x,y) coordinates
of the gold particles were determined using ImageJ. Univariate
K-functions (35) were calculated as described previously and
standardized on the 99% confidence interval (CI) (36–38).
Bootstrap tests to examine differences between replicated point
patterns were constructed as described previously, and statisti-
cal significance was evaluated against 1000 bootstrap samples
(38, 39).
Western blotting
Cells were washed in ice-cold phosphate-buffered saline
(PBS) and lysed for 10 min on ice in buffer containing 50 mM
Tris-Cl (pH 7.5), 75 mM NaCl, 25 mM NaF, 5 mM MgCl2, 5 mM
EGTA, 1 mM DTT, 100 M Na3VO4, 1% Nonidet P-40, and
protease inhibitors. The resulting whole cell lysate was centri-
fuged at 14,000 rpm for 20 min to remove cell debris and 20 g
of the supernatant was analyzed by SDS-PAGE. After SDS-
PAGE, proteins were transferred to PVDF membranes using
semidry Western transfer. After incubation with primary and
secondary antibodies the protein of interest was visualized
using enhanced chemiluminescence (SuperSignal; Pierce) with
ChemiDoc MP System (Bio-Rad) and quantified with ImageJ.
Lipidomic analysis
WT MDCK cells or MDCK cells stably expressing mGFP-
KRASG12V were treated with 1 M G01 or 5 nM STS for 48 h.
Cells were scraped in Dulbecco’s PBS (DPBS) and 1.5 	 106
cells/ml in 300 l was analyzed. Lipid extraction and analysis
using electron spray ionization and MS/MS were performed at
Lipotype, GmbH (Dresden, Germany), as described previously
(40, 41). Automated processing of acquired mass spectra, iden-
tification, and quantification of detected lipid species were
done by LipidXplorer software. Only lipid identifications with a
signal-to-noise ratio 5, an absolute abundance of at least 1
pmol, and a signal intensity 5-fold higher than in corresponding
blank samples were considered for further data analysis. The
abundance of lipids is presented as pmol of lipids/cell, relative
to WT cells.
Lysenin staining
Maltose-binding protein-GFP-lysenin fragment (amino acid
residues 161 to 297) was purified as described previously (22,
23). For lysenin staining, MDCK cells were fixed with 4% PFA,
permeabilized or not permeabilized with 0.05% saponin, and
then incubated with 60 g/ml of maltose-binding protein-
GFP-lysenin for 15 min.
Cell proliferation experiments
Tumor cells or RAS-less MEF cells were seeded in 24-well
plates. After 24 h, cells were treated with vehicle (DMSO) or 5
M G01 for 72 h. The cells were trypsinized and counted. The
cell number of G01-treated cells was normalized to that of the
DMSO-treated cells.
Statistical analysis
Prism (version 5.0c, GraphPad Software) was used for one-
way ANOVA and two-tailed Student’s t tests.
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